EA201270632A1 - 2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций - Google Patents
2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекцийInfo
- Publication number
- EA201270632A1 EA201270632A1 EA201270632A EA201270632A EA201270632A1 EA 201270632 A1 EA201270632 A1 EA 201270632A1 EA 201270632 A EA201270632 A EA 201270632A EA 201270632 A EA201270632 A EA 201270632A EA 201270632 A1 EA201270632 A1 EA 201270632A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- fluoro
- treatment
- viral infections
- methods
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 3
- 241000701022 Cytomegalovirus Species 0.000 abstract 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000037921 secondary disease Diseases 0.000 abstract 2
- 201000006082 Chickenpox Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 208000007514 Herpes zoster Diseases 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 206010046980 Varicella Diseases 0.000 abstract 1
- 229960001997 adefovir Drugs 0.000 abstract 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28134209P | 2009-11-16 | 2009-11-16 | |
| PCT/US2010/056808 WO2011060408A2 (en) | 2009-11-16 | 2010-11-16 | 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201270632A1 true EA201270632A1 (ru) | 2013-01-30 |
Family
ID=43992463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270632A EA201270632A1 (ru) | 2009-11-16 | 2010-11-16 | 2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8946244B2 (enExample) |
| EP (1) | EP2501709A4 (enExample) |
| JP (1) | JP5779799B2 (enExample) |
| KR (2) | KR101840479B1 (enExample) |
| CN (1) | CN102725302B (enExample) |
| AP (1) | AP2012006310A0 (enExample) |
| AU (1) | AU2010319999B2 (enExample) |
| CA (1) | CA2781054A1 (enExample) |
| EA (1) | EA201270632A1 (enExample) |
| IL (1) | IL219748A0 (enExample) |
| MX (1) | MX2012005601A (enExample) |
| PH (1) | PH12012500963B1 (enExample) |
| WO (1) | WO2011060408A2 (enExample) |
| ZA (1) | ZA201204356B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PY0111577A (es) | 2000-05-23 | 2017-01-02 | Idenix Cayman Ltd | Métodos y composiciones para el tratamiento del virus de la hepatitis c |
| RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
| US8816074B2 (en) * | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| US9700560B2 (en) | 2009-11-16 | 2017-07-11 | University Of Georgia Research Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| CN102850402B (zh) * | 2011-06-28 | 2016-08-03 | 李勤耕 | 非环核苷环状磷酸酯类衍生物，其制备方法及医药用途 |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物 |
| CN102603652A (zh) * | 2011-12-27 | 2012-07-25 | 河南师范大学 | 5-甲酰基嘧啶碳环核苷及制备方法 |
| AU2013221571A1 (en) * | 2012-02-14 | 2014-08-28 | University Of Georgia Research Foundation, Inc. | Spiro [2.4] heptanes for treatment of Flaviviridae infections |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| AP3913A (en) | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| HUE029038T2 (en) | 2012-05-25 | 2017-01-30 | Janssen Sciences Ireland Uc | Uracil spirooxetan nucleosides |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| SG11201502750UA (en) | 2012-10-08 | 2015-06-29 | Idenix Pharmaceuticals Inc | 2'-chloro nucleoside analogs for hcv infection |
| CN103804417B (zh) * | 2012-11-13 | 2017-09-19 | 北京美倍他药物研究有限公司 | 抗乙肝病毒药物 |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014124092A2 (en) * | 2013-02-07 | 2014-08-14 | Tobira Therapeutics, Inc. | Lamivudine salts |
| US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| WO2015013352A2 (en) * | 2013-07-25 | 2015-01-29 | Patel Hasmukh B | Nucleoside phosphoramidates and phosphoramidites |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| US9334273B1 (en) | 2014-03-05 | 2016-05-10 | University Of Georgia Research Foundation, Inc. | Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| GEP20217282B (en) | 2015-03-06 | 2021-08-10 | Atea Pharmaceuticals Inc | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| CN106466300B (zh) * | 2015-08-12 | 2019-06-21 | 复旦大学 | 一种装载难溶性药物的复合壳聚糖纳米粒制剂及其制备方法和应用 |
| WO2017127461A1 (en) * | 2016-01-18 | 2017-07-27 | Sensor Electronic Technology, Inc. | Semiconductor device with improved light propagation |
| WO2017155082A1 (ja) | 2016-03-11 | 2017-09-14 | 国立大学法人鹿児島大学 | 抗肝腫瘍ウイルス剤 |
| CN108884005B (zh) * | 2016-04-07 | 2021-11-12 | 佐治亚大学研究基金会 | 2’-氟-6’-亚甲基-碳环腺苷(fmca)和2’-氟-6’-亚甲基-碳环鸟苷(fmcg)的合成 |
| PT3442580T (pt) | 2016-04-11 | 2020-12-23 | Genfit | Métodos de tratamento para doenças colestáticas e fibróticas |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| WO2018092728A1 (ja) * | 2016-11-16 | 2018-05-24 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体 |
| WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
| CN110248951B (zh) | 2017-02-01 | 2022-10-28 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| KR102337922B1 (ko) | 2018-04-19 | 2021-12-09 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| KR20190121956A (ko) | 2018-04-19 | 2019-10-29 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| JP7496132B2 (ja) * | 2018-08-31 | 2024-06-06 | 国立大学法人 鹿児島大学 | 核酸アナログ及び抗ｂ型肝炎ウイルス剤 |
| CN109846887B (zh) * | 2019-03-22 | 2022-12-09 | 南京大学 | 2-氨基嘌呤-6（h）硫酮在制备单纯疱疹病毒的抑制剂中的应用 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| WO2025207435A1 (en) * | 2024-03-25 | 2025-10-02 | University Of Georgia Research Foundation, Inc. | 2'-fluoro-6'-methylene carbocyclic nucleos(t)ides as potent antiviral agents for the treatment of wild-type and mutant hepatitis b virus (hbv) infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4396623A (en) | 1981-08-26 | 1983-08-02 | Southern Research Institute | Carbocyclic analogs of uracil nucleosides as antiviral agents |
| GB8520553D0 (en) * | 1985-08-16 | 1985-09-25 | Glaxo Group Ltd | Chemical compound |
| CN100387237C (zh) * | 1998-08-10 | 2008-05-14 | 艾丹尼克斯(开曼)有限公司 | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 |
| CA2405502A1 (en) * | 2000-03-29 | 2001-10-04 | Georgetown University | Method of treating hepatitis delta viral infection |
| AU2001259754A1 (en) | 2000-05-10 | 2001-11-20 | Phycogen, Inc. | Transgenic plants incorporating_genes of zostera marina |
| SI1355916T1 (sl) * | 2001-01-22 | 2007-04-30 | Merck & Co Inc | Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze |
| CN1678326A (zh) * | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US8816074B2 (en) * | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
-
2010
- 2010-11-16 WO PCT/US2010/056808 patent/WO2011060408A2/en not_active Ceased
- 2010-11-16 MX MX2012005601A patent/MX2012005601A/es not_active Application Discontinuation
- 2010-11-16 EP EP10830894.1A patent/EP2501709A4/en not_active Withdrawn
- 2010-11-16 US US13/510,090 patent/US8946244B2/en active Active
- 2010-11-16 KR KR1020127015444A patent/KR101840479B1/ko not_active Expired - Fee Related
- 2010-11-16 CA CA2781054A patent/CA2781054A1/en not_active Abandoned
- 2010-11-16 JP JP2012539968A patent/JP5779799B2/ja not_active Expired - Fee Related
- 2010-11-16 PH PH1/2012/500963A patent/PH12012500963B1/en unknown
- 2010-11-16 AP AP2012006310A patent/AP2012006310A0/xx unknown
- 2010-11-16 AU AU2010319999A patent/AU2010319999B2/en not_active Ceased
- 2010-11-16 EA EA201270632A patent/EA201270632A1/ru unknown
- 2010-11-16 KR KR1020187002212A patent/KR101961601B1/ko not_active Expired - Fee Related
- 2010-11-16 CN CN201080062516.9A patent/CN102725302B/zh not_active Expired - Fee Related
-
2012
- 2012-05-13 IL IL219748A patent/IL219748A0/en unknown
- 2012-06-13 ZA ZA2012/04356A patent/ZA201204356B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101840479B1 (ko) | 2018-03-20 |
| HK1172628A1 (zh) | 2013-04-26 |
| US20130005677A1 (en) | 2013-01-03 |
| MX2012005601A (es) | 2012-08-01 |
| WO2011060408A2 (en) | 2011-05-19 |
| JP5779799B2 (ja) | 2015-09-16 |
| KR101961601B1 (ko) | 2019-03-25 |
| IL219748A0 (en) | 2012-07-31 |
| CN102725302A (zh) | 2012-10-10 |
| EP2501709A2 (en) | 2012-09-26 |
| PH12012500963B1 (en) | 2018-08-10 |
| PH12012500963A1 (en) | 2018-05-15 |
| ZA201204356B (en) | 2013-02-27 |
| CA2781054A1 (en) | 2011-05-19 |
| AU2010319999B2 (en) | 2014-01-16 |
| CN102725302B (zh) | 2016-04-06 |
| AP2012006310A0 (en) | 2012-06-30 |
| US8946244B2 (en) | 2015-02-03 |
| KR20120092153A (ko) | 2012-08-20 |
| KR20180014179A (ko) | 2018-02-07 |
| WO2011060408A3 (en) | 2011-10-13 |
| JP2013510904A (ja) | 2013-03-28 |
| AU2010319999A1 (en) | 2012-06-21 |
| EP2501709A4 (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012158552A3 (en) | 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections | |
| WO2011060408A3 (en) | 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections | |
| JP2024055867A (ja) | 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物 | |
| MX2015005500A (es) | Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. | |
| EP4319763A4 (en) | MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES | |
| WO2010118367A3 (en) | Antiviral pyrimidines | |
| West et al. | Toll-like receptor sensing of human herpesvirus infection | |
| Albanese et al. | Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host | |
| Jennings et al. | Type I interferon signaling enhances CD8+ T cell effector function and differentiation during murine gammaherpesvirus 68 infection | |
| Hopcraft et al. | Tumour viruses and innate immunity | |
| WO2009091388A3 (en) | Triazines and related compounds having antiviral activity, compositions and methods thereof | |
| Taylor et al. | Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV | |
| Ullah et al. | Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation | |
| Le‐Trilling et al. | Attack, parry and riposte: molecular fencing between the innate immune system and human herpesviruses | |
| Dharnidharka | Peripheral blood Epstein–Barr viral nucleic acid surveillance as a marker for posttransplant cancer risk | |
| DE60112790D1 (de) | Amidderivate | |
| Berenstein et al. | Recombination rates along the entire Epstein Barr virus genome display a highly heterogeneous landscape | |
| Li et al. | Repurposing licensed drugs with activity against Epstein–Barr virus for treatment of multiple sclerosis: a systematic approach | |
| Gan et al. | Manipulation of ubiquitin/SUMO pathways in human herpesviruses infection | |
| Domingo-Calap | Viral evolution and Immune responses | |
| Ocheni et al. | EBV-associated malignancies | |
| MY169510A (en) | Detection of epstein -barr virus (ebv) in nasopharyngeal cancer | |
| Zhang et al. | Immune evasion strategies of the human gamma‐herpesviruses: Implications for viral tumorigenesis | |
| Khrustalev et al. | Percent of highly immunogenic amino acid residues forming B-cell epitopes is higher in homologous proteins encoded by GC-rich genes | |
| Boivin et al. | Disseminated herpes simplex virus type 1 primary infection in a healthy individual |